Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Pleural Effusion 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Lung Neoplasms 1Advanced Solid Tumors 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Cdc25C phosphatase (211-221) × Clear all
NCT04953962 2023-08-15

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

CanBas Co. Ltd.

Phase 2 Completed
36 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00700336 2021-07-20

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

CanBas Co. Ltd.

Phase 1/2 Completed
69 enrolled 9 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03113188 2021-03-10

CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

CanBas Co. Ltd.

Phase 1 Completed
47 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00942825 2017-05-24

CBP08-02

CanBas Co. Ltd.

Phase 2 Completed
195 enrolled 8 charts
Thoracic

Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion

NCT00551512 2017-03-14

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors

CanBas Co. Ltd.

Phase 1 Completed
48 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡